(0.31%) 5 115.88 points
(0.30%) 38 355 points
(0.36%) 15 985 points
(-0.98%) $83.03
(5.36%) $2.03
(0.29%) $2 354.10
(0.35%) $27.63
(4.10%) $959.95
(-0.26%) $0.932
(-0.44%) $10.98
(-0.57%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD...
Stats | |
---|---|
本日の出来高 | 2 288.00 |
平均出来高 | 21 587.00 |
時価総額 | 303.46M |
EPS | $0 ( 2024-03-06 ) |
次の収益日 | ( $0.0600 ) 2024-05-22 |
Last Dividend | $0.00600 ( 2013-06-13 ) |
Next Dividend | $0 ( N/A ) |
P/E | 35.20 |
ATR14 | $0.0250 (0.47%) |
Kamada Ltd 財務諸表
Annual | 2023 |
収益: | $144.76M |
総利益: | $52.59M (36.33 %) |
EPS: | $0.170 |
FY | 2023 |
収益: | $144.76M |
総利益: | $52.59M (36.33 %) |
EPS: | $0.170 |
FY | 2022 |
収益: | $129.34M |
総利益: | $46.70M (36.11 %) |
EPS: | $-0.0518 |
FY | 2021 |
収益: | $103.64M |
総利益: | $30.33M (29.26 %) |
EPS: | $-0.0500 |
Financial Reports:
No articles found.
Kamada Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.00600 | 2013-06-13 |
Last Dividend | $0.00600 | 2013-06-13 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.00600 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.72 | -- |
Div. Sustainability Score | 9.03 | |
Div.Growth Potential Score | 2.37 | |
Div. Directional Score | 5.70 | -- |
Year | Amount | Yield |
---|---|---|
2013 | $0.00600 | 0.06% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0574 | 1.500 | 8.85 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0235 | 1.200 | 9.22 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0398 | 1.500 | -0.669 | -1.003 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.43 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 1.554 | 0.800 | 5.56 | 4.45 | [0.8 - 2.5] |
cashRatioTTM | 1.122 | 1.500 | 4.88 | 7.32 | [0.2 - 2] |
debtRatioTTM | 0.0250 | -1.500 | 9.58 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 6.53 | 1.000 | 8.69 | 8.69 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0760 | 2.00 | 9.97 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.0278 | 2.00 | -0.0139 | -0.0278 | [0 - 20] |
debtEquityRatioTTM | 0.0364 | -1.500 | 9.85 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.389 | 1.000 | 6.84 | 6.84 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0587 | 1.000 | -0.827 | -0.827 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.496 | 1.000 | 8.36 | 8.36 | [0.2 - 2] |
assetTurnoverTTM | 0.410 | 0.800 | -0.598 | -0.478 | [0.5 - 2] |
Total Score | 9.03 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 35.73 | 1.000 | 6.49 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0398 | 2.50 | -0.430 | -1.003 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.0278 | 2.00 | -0.00928 | -0.0278 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0760 | 2.00 | 9.97 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.633 | 1.500 | 9.12 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0302 | 1.000 | -1.744 | 0 | [0.1 - 0.5] |
Total Score | 2.37 |
Kamada Ltd
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。